{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:59:15Z","timestamp":1777420755693,"version":"3.51.4"},"reference-count":70,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2014,5,8]],"date-time":"2014-05-08T00:00:00Z","timestamp":1399507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:p>Objective: To review the use of sofosbuvir for the treatment of chronic hepatitis C virus (HCV). Data Sources: Review and nonreview articles were identified through MEDLINE (1996-April 2014), citations of articles, and meeting abstracts using keywords, including NS5B polymerase inhibitor, GS-7977, sofosbuvir, direct-acting antiviral (DAA), and others. Study Selection and Data Extraction: Phase 1, 2, and 3 studies describing dose-ranging potential, pharmacokinetics, efficacy, safety, and tolerability of sofosbuvir were identified. Data Synthesis: Sofosbuvir is an NS5B polymerase inhibitor that was approved for use by the Food and Drug Administration in December 2013 for the treatment of chronic HCV in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) for genotype 1. Additionally, it has been evaluated with other oral DAAs, such as simeprevir and others in the pipeline. It is not recommended as monotherapy because of lower sustained virological response (SVR) rates in clinical studies. Most of the treatment regimens are 12 weeks in duration; however, certain populations require a longer duration. Sofosbuvir has activity against all 6 genotypes, although most clinical trials evaluated genotypes 1 to 3. Sofosbuvir has a favorable safety and tolerability profile, making it a recommended first-line agent for chronic HCV infection. Conclusion: In clinical trials, 12 weeks of sofosbuvir with concomitant peg-IFN and RBV therapy in treatment-na\u00efve and experienced HCV genotype 1 patients resulted in SVR rates of &gt;90%. An all-oral regimen of sofosbuvir and RBV is highly effective for genotype 2 and 3 patients. Sofosbuvir was found to be tolerable with minimal adverse effects (AEs), and no treatment discontinuations occurred secondary to drug related AEs..<\/jats:p>","DOI":"10.1177\/1060028014534194","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T05:52:40Z","timestamp":1399614760000},"page":"1019-1029","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":47,"title":["Sofosbuvir"],"prefix":"10.1177","volume":"48","author":[{"given":"Lucia","family":"Rose","sequence":"first","affiliation":[{"name":"Western New England University, Springfield, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany E.","family":"Bias","sequence":"additional","affiliation":[{"name":"Hahnemann University Hospital, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton B.","family":"Mathias","sequence":"additional","affiliation":[{"name":"Western New England University, Springfield, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey B.","family":"Trooskin","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"Fong","sequence":"additional","affiliation":[{"name":"MCPHS University-Worcester\/Manchester, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,5,8]]},"reference":[{"key":"bibr1-1060028014534194","unstructured":"World Health Organization. Global alert and response (GAR): hepatitis C. http:\/\/www.who.int\/csr\/disease\/hepatitis\/whocdscsrlyo2003\/en\/index4.html. Accessed April 17, 2014."},{"key":"bibr2-1060028014534194","unstructured":"World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. http:\/\/www.who.int\/csr\/disease\/hepatitis\/GHP_Framework_En.pdf. Accessed April 17, 2014."},{"key":"bibr3-1060028014534194","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"bibr4-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02494.x"},{"key":"bibr5-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1038\/nature04078"},{"key":"bibr6-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3253"},{"key":"bibr7-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"bibr8-1060028014534194","first-page":"S286","volume":"11","author":"McHutchison JG","year":"2005","journal-title":"Am J Manag Care"},{"key":"bibr9-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02537.x"},{"key":"bibr10-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"bibr11-1060028014534194","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"bibr12-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"bibr13-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P430"},{"key":"bibr14-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"bibr15-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"key":"bibr16-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"bibr17-1060028014534194","doi-asserted-by":"crossref","first-page":"227A","DOI":"10.1016\/S0168-8278(13)60557-7","volume":"58","author":"Di Bisceglie AM","year":"2013","journal-title":"Hepatology"},{"key":"bibr18-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12523"},{"key":"bibr19-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"bibr20-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00399-10"},{"key":"bibr21-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2011.05.003"},{"key":"bibr22-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.775246"},{"key":"bibr23-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13515825"},{"key":"bibr24-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"bibr25-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.161802"},{"key":"bibr26-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00054-12"},{"key":"bibr27-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit827"},{"key":"bibr28-1060028014534194","first-page":"551A","volume":"56","author":"Svarovskaia ES","year":"2012","journal-title":"Hepatology"},{"key":"bibr29-1060028014534194","doi-asserted-by":"crossref","first-page":"1091A","DOI":"10.1002\/hep.26880","volume":"58","author":"Svarovskaia ES","year":"2013","journal-title":"Hepatology"},{"key":"bibr30-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"bibr31-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"bibr32-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"bibr33-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"bibr34-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"bibr35-1060028014534194","first-page":"711A","volume":"56","author":"Han B","year":"2012","journal-title":"Hepatology"},{"key":"bibr36-1060028014534194","doi-asserted-by":"crossref","first-page":"739A","DOI":"10.1002\/hep.26361","volume":"58","author":"Rajyaguru S","year":"2013","journal-title":"Hepatology"},{"key":"bibr37-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01262-12"},{"key":"bibr38-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01263-12"},{"key":"bibr39-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61142-8"},{"key":"bibr40-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61113-1"},{"key":"bibr41-1060028014534194","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.12.104"},{"key":"bibr42-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir076"},{"key":"bibr43-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.039"},{"key":"bibr44-1060028014534194","unstructured":"US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Guidance for Industry. Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment. Rockville, MD: US FDA CDER; 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM225333.pdf. Accessed February 10, 2014."},{"key":"bibr45-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.018"},{"key":"bibr46-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01598-08"},{"key":"bibr47-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.007"},{"key":"bibr48-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"bibr49-1060028014534194","volume-title":"Program and Abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases","author":"Jacobson I","year":"2013"},{"key":"bibr50-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"bibr51-1060028014534194","doi-asserted-by":"crossref","first-page":"733A","DOI":"10.1002\/hep.26363","volume":"58","author":"Zeuzem S","year":"2013","journal-title":"Hepatology"},{"key":"bibr52-1060028014534194","first-page":"544A","volume":"54","author":"Denning JM","year":"2011","journal-title":"Hepatology"},{"key":"bibr53-1060028014534194","first-page":"431A","volume":"58","author":"Mogalian E","year":"2013","journal-title":"Hepatology"},{"key":"bibr54-1060028014534194","first-page":"1072A","volume":"56","author":"German P","year":"2012","journal-title":"Hepatology"},{"key":"bibr55-1060028014534194","first-page":"1067A","volume":"56","author":"Kirby B","year":"2012","journal-title":"Hepatology"},{"key":"bibr56-1060028014534194","first-page":"1063A","volume":"56","author":"Mathias A","year":"2012","journal-title":"Hepatology"},{"key":"bibr57-1060028014534194","first-page":"433A","volume":"58","author":"German P","year":"2013","journal-title":"Hepatology"},{"key":"bibr58-1060028014534194","unstructured":"Sovaldi\u2122 oral tablets, sofosbuvir oral tablets [product information]. Foster City, CA: Gilead Sciences, Inc; 2013."},{"key":"bibr59-1060028014534194","doi-asserted-by":"crossref","first-page":"313A","DOI":"10.1002\/hep.26826","volume":"58","author":"Sulkowski MS","year":"2013","journal-title":"Hepatology"},{"key":"bibr60-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00926.x"},{"key":"bibr61-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21646"},{"key":"bibr62-1060028014534194","first-page":"314A","volume":"58","author":"Curry MP","year":"2013","journal-title":"Hepatology"},{"key":"bibr63-1060028014534194","first-page":"732A","volume":"58","author":"Forns X","year":"2013","journal-title":"Hepatology"},{"key":"bibr64-1060028014534194","volume-title":"Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases","author":"Charlton MR","year":"2013"},{"key":"bibr65-1060028014534194","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00004"},{"key":"bibr66-1060028014534194","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00005"},{"key":"bibr67-1060028014534194","unstructured":"Gilead. US Food and Drug Administration Approves Gilead\u2019s Sovaldi\u2122 (sofosbuvir) for the treatment of chronic hepatitis C. http:\/\/www.gilead.com\/news\/press-releases\/2013\/12\/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c#sthash.T9uTbSWK.dpuf. Accessed December 6, 2013."},{"key":"bibr68-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27151"},{"key":"bibr69-1060028014534194","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27010"},{"key":"bibr70-1060028014534194","unstructured":"AASLD and IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org\/full-report\/initial-treatment-hcv-infection-patients-starting-treatment. Accessed February 1, 2013."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014534194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028014534194","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014534194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:07Z","timestamp":1777374907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028014534194"}},"subtitle":["A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection"],"short-title":[],"issued":{"date-parts":[[2014,5,8]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1177\/1060028014534194"],"URL":"https:\/\/doi.org\/10.1177\/1060028014534194","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,8]]}}}